Back to all papers

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning

May 7, 2026medrxiv logopreprint

Authors

Karlsson, L.,Strandberg, O.,Smith, R.,Tang, W.,Arvidsson, I.,Astrom, K.,Oliviera Hauer, K.,Janelidze, S.,Stomrud, E.,Palmqvist, S.,Verghese, P. B.,Braunstein, J. B.,Alzheimer's Disease Neuroimaging Initiative,,PREVENT-AD Research Group,,Klein, G.,Shcherbinin, S.,Jagust, W. J.,Villeneuve, S.,La Joie, R.,Rabinovici, G. D.,Mattsson-Carlgren, N.,Vogel, J. W.,Hansson, O.

Affiliations (1)

  • Clinical Memory Research Unit, Department of Clinical Sciences, Lund University

Abstract

Tau protein aggregation in the brain is a hallmark of Alzheimers disease (AD). Positron emission tomography (PET) is the only in vivo method to visualize tau pathology and estimate both its burden and regional distribution, but the use of tau-PET is constrained by high cost and limited accessibility. Here, we develop a deep learning model to synthesize tau-PET scans from more accessible data: structural magnetic resonance imaging (MRI), demographics, and when available, blood biomarkers. We included 5,191 participants across the AD continuum or with another neurological disorder from 13 cohorts (mean age 70 years, 51% female) and optimized a 3D U-Net neural network with residual and attention units for this task. In held-out test data, synthetic tau-PET reliably modeled tau burden, with correlations of R=0.77-0.86 with true tau-PET across individuals in common AD regions of interest. Spatial similarity between synthetic and true tau-PET was likewise high, with mean regional correlation of R=0.75. Synthetic scans also captured clinically meaningful prognostic information comparable to true tau-PET, including distinction between early (HR=12, p<0.001) and late (HR=45, p<0.001) stages of tau accumulation. These findings demonstrate that clinically informative synthetic tau-PET scans can be generated from widely available modalities using deep learning, potentially offering a scalable and cost-effective approach for estimating tau AD pathology in the brain.

Topics

neurology

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.